Clinical Cell and Vaccine Production Facility
The Clinical Cell and Vaccine Production Facility (CVPF) renders bench-to-bedside translational medicine a reality. Equipped with state of the art facilities, the CVPF manufactures cell and gene biotherapeutics and is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) as well as by the College of American Pathologists (CAP). Further, the CVPF is the only GMP (good manufacturing practices) compliant facility on campus and functions as an NCI approved Abramson Cancer Center (ACC) Shared Resource. As an ACC Shared Resource and Path and BioResources core facility, the CVPF supports numerous investigational new drug (IND) protocols. Current protocols target a variety of disease indications (primarily HIV, adult and pediatric cancers, and stroke); many more trials are in development and, once approved, will further expand the scope of diseases targeted for cell and gene therapy. For more information on current trials, explore our “Clinical Trials” page.
Current Clinical Trials
  • Cancer Trials
  • HIV Trials

CTL019 Therapy: Recent Publication

The CVPF is excited to announce a recent review of CART therapy, published in Blood on 21 May 2015. For the full research article, please click here.

CD19-targeted chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia

Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A. Grupp


Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with minimal improvement in outcomes seen in more than two decades despite advances in upfront therapy and improved survival for de novo ALL. Adoptive transfer of T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory populations. Complete remission (CR) rates as high as 90% have been reported in children and adults with relapsed and refractory ALL treated with CAR-modified T cells targeting the B cell specific antigen CD19. Distinct CAR designs across several studies have produced similar promising CR rates, an encouraging finding. Even more encouraging are durable remissions observed in some patients without additional therapy. Duration of remission and CAR-modified T cell persistence require further study and more mature follow-up, but emerging data suggests these factors may distinguish CAR designs. Supraphysiologic T cell proliferation, a hallmark of this therapy, contributes to both efficacy and the most notable toxicity, cytokine release syndrome (CRS), posing a unique challenge for toxicity management. This review will discuss the current landscape of CD19 CAR clinical trials, CRS pathophysiology and management, and remaining challenges


CD19-targeted CARs have paved the way for engineered T cell therapies with high response rates and durable remissions reported. These results are unprecedented in patients without curative options. As new innovations in CAR design and manufacture develop and toxicity management evolves, the potential uses for this therapy will be expanded, as will access.

Have you ever thought about running the Philadelphia Marathon?   
Did you know you have three distances from which to choose?

Lace up your running shoes!


  • Emily Whitehead, the first pediatric patient treated with CART19, has founded her own foundation to raise money for all types of cancers and cancer centers. 
  • What better way to show our continued support for her and her family than building a team from CCI to run for her!


Click here to get started.
This page will provide you with full instructions on how to register.

Fundraising and Race Options
November 21, 2015 – 8k ($150 fundraising minimum)
November 22, 2015 – Half marathon ($350 fundraising minimum)
November 22, 2015 – Full marathon ($500 fundraising minimum)

A nanoflight View of Immune Cells Engineered to Fight Cancer
Sample Preparation by Ray Meade,
Electron Microscopy Resource Lab, Perelman School of Medicine
nanoflight video by © Scientific Photography – Stefan Diller, Germany

Dr. Bruce Levine’s Twitter Feed